Citadel Advisors
ARLZ

Citadel Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Citadel Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,800
Closed -$7K – 10176
2018
Q2 		$7K Buy
20,800
+6,200
+42% +$5.09K ﹤0.01% 8730
2018
Q1 		$22K Sell
14,600
-8,400
-37% -$14.7K ﹤0.01% 8111
2017
Q4 		$33K Buy
23,000
+1,700
+8% +$2.79K ﹤0.01% 7750
2017
Q3 		$49K Buy
+21,300
New +$28.5K ﹤0.01% 7190
2017
Q2 		– Sell
-22,500
Closed -$48K – 8648
2017
Q1 		$48K Sell
22,500
-6,600
-23% -$24.8K ﹤0.01% 7053
2016
Q4 		$128K Sell
29,100
-12,200
-30% -$57.9K ﹤0.01% 6581
2016
Q3 		$200K Buy
+41,300
New +$188K ﹤0.01% 6312
2016
Q2 		– Sell
-18,000
Closed -$64K – 8006
2016
Q1 		$64K Buy
+18,000
New +$92.8K ﹤0.01% 6185

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's ARLZ Position: Q3 2018 in Review

Citadel Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 16,471 shares — an estimated $6K sold.

Citadel Advisors first reported a position in ARLZ in Q1 2016 and held it in 7 quarters. The position peaked at $221K in Q4 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Citadel Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Citadel Advisors sold 16,471 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $6K.
  • Citadel Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 7 quarters.
  • Citadel Advisors's Aralez Pharmaceuticals Inc. position peaked at $221K in Q4 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.